ALSO NOTED: Burrill bullish on M&As; Nebivolol wins approval; Arrowhead Research names CEO; and much more...

> G. Steven Burrill is touting the (relative) success of his Burrill Biotech Select Index compared to the swooning Nasdaq and sounds quite bullish about the impact of M&As in biotech. Report

> The FDA has approved an NDA from Forest Laboratories and Mylan for nebivolol, or Bystolic, for hypertension. Forest is planning to launch in January, saying that the FDA's concerns about a backup facility can be dealt with quickly. Release

> Apparently, GlaxoSmithKline's dynamic duo is worth $4.1 million each. The two execs passed over for the CEO job--Chris Viehbacher (photo) and David Stout (photo)--will each get a retention package worth that much if shareholders approve. Report

> Prepping for his January inauguration, CEO-in-waiting Bernard Poussot (photo) has tapped a handful of current Wyeth-ites to fill top positions in the company. Report 

> Henry Waxman, chairman of the House Committee on Oversight and Government Reform, is protesting an off-label marketing "loophole." Report

> Chutes & Ladders: Arrowhead Research has named Christopher Anzalone as CEO and is in the process of buying the private equity group he founded. Report

> AEterna Zentaris has closed on the $3.2 million sale of Echelon Biosciences to Frontier Scientific. Release

And Finally… Intelligent software may be the key to developing the perfect artificial hand. Release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.